Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Active Months Ahead For mHealth Regulatory Policymaking

This article was originally published in The Pink Sheet Daily

Executive Summary

Multiple guidances, frameworks and legislative activity on mHealth are expected to surface this fall and could have major implications on how the emerging industry is regulated.

You may also be interested in...



IRB, HIPAA Changes To Be Folded Into 21st Century Cures Bill Next Year

Centralized institutional review board approvals for device trials, and removal of HIPAA privacy provisions that block registry data-sharing are among the ideas that are likely to make it into a draft bill planned for release in January as the next step in the House’s 21st Century Cures initiative.

Software Oversight Softened: FDA Nixes Medical Device Data Systems Enforcement

Makers of software that passively stores, transfers, formats or displays medical device data no longer need to worry about the quality system regulation or other basic device requirements for the products, according to a June 20 draft guidance.

Health IT Deregulation Bill Introduced In Senate, With Powerful Industry Backers

The PROTECT Act, which attempts to respond to some criticisms of the House SOFTWARE Act, aims to restrict FDA’s oversight of health information technology. It is backed by IBM and Verizon, among others.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076600

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel